There is no upcoming dividend defined for Argenx.
There is no set last day on which buying Argenx shares generates the possibility of earning dividends.
There has been no final dividend for Argenx.
Argenx S.E., listed on the Brussels Stock Exchange, BATS EU, NASDAQ, London, Frankfurt and Vienna, using the ticker symbol ARGX, has not paid dividends to its shareholders to date.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Argenx Dividends
Dividend calendar of Argenx
There is no Dividend Calendar of Argenx defined for 2023.
Historical annual dividend yields of Argenx
Dividend yield of Argenx vs. the sector
Dividend yield history in Argenx
Dividend history of Argenx
Argenx has never distributed dividends, so it has an empty dividend history.
Argenx dividend capture strategy
Information about Argenx
Argenx S.E., is a multinational company dedicated to the health industry, specifically to biotechnology, developing medical treatments and therapies to combat autoimmune diseases.
It was created in 2008 in Amsterdam, The Netherlands, its name is a derivation of the myth of the Argonauts, which refers to the power of teamwork, which in this case are engaged in seeking immunological solutions in order to help improve the lives of their patients, their products are also present in Belgium, United Kingdom, Japan, United States, Canada, Switzerland, Germany, Italy and France.
The main drug marketed is "efgartigimod", indicated for the treatment of diseases such as idiopathic inflammatory myopathy, immune thrombocytopenia, myasthenia gravis, bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus.
They also develop and market products such as ARGX-109, ARGX-112, ARGX-114, which is an antibody designed to control the mesenchymal-epithelial transition, ARGX-115, a specialized drug for the treatment of cancer, ARGX-116, ARGX-117 indicated for severe autoimmune diseases, ARGX-118 used in inflammation of the respiratory tract, ARGX-119, an antibody, among others.
Since its creation to date, it has made a series of strategic alliances with several companies to increase its processes and licenses, including Genmab, Staten Biotechnology, Pharma, AbbVie, LEO Pharma, Genor Biopharma, Zai Lab Limited, Université Catholique de Louvain, BioWa, Shire International GmbH, AgomAb Therapeutics, NYU Langone Health, Broteio, the University of Texas, among others.
Frequently asked questions about Argenx dividends
Argenx is listed on the Bolsa de Bruselas and is part of the BEL20.
Argenx has the Ticker or stock code ARGX.
Argenx belongs to the Health Care sector and the Biotechnology industry.
The CEO of Argenx in 2023 is Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc..
At this moment, the value of a Argenx share is 402.20€.
Argenx does not have a growing dividend program. Dividends have not shown a steady growth in the last 5 years.